« Problems in Healthcare: Biotech Edition | Main | Our Take on Google Radio »

Winner's Curse: Stent Wars Edition

Boston Scientific (NYSE: BSX) upped their buyout offer for Guidant (NYSE: GDT) once again in hopes of wresting the company away from Johnson & Johnson (NYSE: JNJ).  The new bid is higher than the original J&J offer, which had been lowered when Guidant's regulatory problems became a concern for J&J.  Confused?  Well, here's a timeline of the whole affair to bring you up to speed.  I suspect we haven't seen the last chapter of this DVD quite yet.

By the way, if Boston Scientific pulls this off, it will be quite an accomplishment. Their latest buyout offer is for over $25 billion but their market cap is only around $19 billion.

January 17, 2006 in Healthcare |

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a00d8341cd1cd53ef00d8355a95cf69e2

Listed below are links to weblogs that reference Winner's Curse: Stent Wars Edition:

Comments

Verify your Comment

Previewing your Comment

Posted by:  | 

This is only a preview. Your comment has not yet been posted.

Working...
Your comment could not be posted. Error type:
Your comment has been posted. Post another comment

The letters and numbers you entered did not match the image. Please try again.

As a final step before posting your comment, enter the letters and numbers you see in the image below. This prevents automated programs from posting comments.

Having trouble reading this image? View an alternate.

Working...

Post a comment

What is This?


  • The Stalwart is a blog written by Joseph Weisenthal, covering such topics as stocks, business, economics, politics, technology, gambling, chess, poker, economics, current events, music, math, Chinese food, science, randomness, kurtosis, sports, evolutionary fitness, and anything else of the author's choosing. The words contained herein are the author's own, not affiliated with any other firm or employer.

About

Stats



Advertisements